144,404 Shares in Sensei Biotherapeutics, Inc. $FTH Acquired by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. purchased a new position in Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 144,404 shares of the company's stock, valued at approximately $3,610,000. Alyeska Investment Group L.P. owned about 0.56% of Sensei Biotherapeutics as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in shares of Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company's stock valued at $123,000 after purchasing an additional 1,100 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Stempoint Capital LP purchased a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth $4,188,000. Finally, Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth $22,758,000. Hedge funds and other institutional investors own 10.50% of the company's stock.

Sensei Biotherapeutics Price Performance

Sensei Biotherapeutics stock opened at $34.51 on Wednesday. Sensei Biotherapeutics, Inc. has a fifty-two week low of $7.45 and a fifty-two week high of $37.90. The stock has a market cap of $891.74 million, a P/E ratio of -0.24 and a beta of -0.28. The firm has a 50-day moving average price of $28.93.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($5.04) by $2.20. Sell-side analysts forecast that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

FTH has been the subject of several analyst reports. Raymond James Financial started coverage on Sensei Biotherapeutics in a research report on Friday, July 31st. They set an "outperform" rating and a $56.00 price objective for the company. JonesTrading started coverage on Sensei Biotherapeutics in a research report on Tuesday, August 4th. They set a "buy" rating and a $55.00 target price on the stock. Citigroup started coverage on Sensei Biotherapeutics in a research note on Friday, May 22nd. They set a "buy" rating and a $55.00 target price for the company. Robert W. Baird began coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They issued an "outperform" rating and a $57.00 price target for the company. Finally, BTIG Research reiterated a "buy" rating and issued a $55.00 price target on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $55.00.

Insiders Place Their Bets

In other Sensei Biotherapeutics news, CEO Anand Kiran Parikh purchased 2,806 shares of the firm's stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brian C. Stephenson acquired 9,391 shares of the stock in a transaction on Wednesday, June 24th. The shares were acquired at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the transaction, the chief financial officer directly owned 26,804 shares in the company, valued at $700,388.52. The trade was a 53.93% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 49,494 shares of company stock worth $1,188,822 over the last ninety days. Corporate insiders own 7.00% of the company's stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.

Want to see what other hedge funds are holding FTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source